Integer (NYSE:ITGR) Sets New 52-Week High at $121.63

Integer Holdings Co. (NYSE:ITGR)’s share price hit a new 52-week high on Wednesday . The stock traded as high as $121.63 and last traded at $121.62, with a volume of 77320 shares. The stock had previously closed at $117.91.

Wall Street Analyst Weigh In

A number of brokerages have commented on ITGR. Benchmark upped their price target on shares of Integer from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, March 28th. KeyCorp upped their price target on shares of Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a research report on Tuesday, April 9th. CL King began coverage on shares of Integer in a research report on Thursday, March 14th. They set a “buy” rating and a $137.00 price target on the stock. Finally, Bank of America raised shares of Integer from a “neutral” rating to a “buy” rating and upped their price target for the company from $105.00 to $135.00 in a research report on Monday, April 15th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $120.50.

Integer Stock Down 9.8 %

The firm’s fifty day moving average price is $112.91 and its two-hundred day moving average price is $99.57. The stock has a market cap of $3.73 billion, a price-to-earnings ratio of 41.36, a price-to-earnings-growth ratio of 1.63 and a beta of 1.10. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.80 and a quick ratio of 1.71.

Integer (NYSE:ITGR) last announced its quarterly earnings data on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.05. Integer had a net margin of 5.68% and a return on equity of 10.80%. The firm had revenue of $413.15 million for the quarter, compared to analyst estimates of $409.04 million. During the same quarter in the prior year, the business earned $1.11 earnings per share. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. Sell-side analysts forecast that Integer Holdings Co. will post 5.31 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integer

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Integer by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 3,843,992 shares of the medical equipment provider’s stock worth $301,484,000 after acquiring an additional 15,300 shares during the last quarter. Victory Capital Management Inc. raised its holdings in shares of Integer by 8.9% in the 3rd quarter. Victory Capital Management Inc. now owns 1,632,549 shares of the medical equipment provider’s stock worth $128,041,000 after acquiring an additional 133,898 shares during the last quarter. FMR LLC raised its holdings in shares of Integer by 12.8% in the 3rd quarter. FMR LLC now owns 863,938 shares of the medical equipment provider’s stock worth $67,759,000 after acquiring an additional 97,851 shares during the last quarter. Fuller & Thaler Asset Management Inc. raised its holdings in shares of Integer by 497.0% in the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 536,343 shares of the medical equipment provider’s stock worth $42,065,000 after acquiring an additional 446,508 shares during the last quarter. Finally, abrdn plc raised its holdings in shares of Integer by 0.6% in the 4th quarter. abrdn plc now owns 520,646 shares of the medical equipment provider’s stock worth $51,586,000 after acquiring an additional 3,013 shares during the last quarter. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.